NCT05395052 - FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

August 11, 2023

Study Completion Date

August 11, 2023

Conditions

Non Small Cell Lung CancerColorectal CancerBreast CancerOvarian CancerPancreatic CancerHead and Neck CancerGastroEsophageal Cancer

Interventions

DRUG

FT536

FT536 is an allogeneic natural killer (NK)-cell immunotherapy

DRUG

Cyclophosphamide

Lympho-conditioning agent

DRUG

Fludarabine

Lympho-conditioning agent

DRUG

IL-2

For Cohort AA ONLY: To be combined with FT536 at the MTD or MAD

COMBINATION_PRODUCT

Avelumab

Monoclonal antibody

COMBINATION_PRODUCT

Pembrolizumab

For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.

COMBINATION_PRODUCT

Nivolumab

For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.

COMBINATION_PRODUCT

Atezolizumab

For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.

COMBINATION_PRODUCT

Trastuzumab

Monoclonal antibody

COMBINATION_PRODUCT

Cetuximab

Monoclonal antibody

COMBINATION_PRODUCT

Amivantamab

Monoclonal antibody

DRUG

IL-2

For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD

Trial Locations (5)

28078

Carolina BioOncology Institute, Huntersville

78229

NEXT Oncology, San Antonio

85258

Honor Health Research Institute, Scottsdale

90404

UCLA Division of Hematology-Oncology, Los Angeles

07601

Hackensack University Medical Center - John Theurer Cancer Center, Hackensack